
    
      Patients whose final manufactured tisagenlecleucel batches do not meet the approved local
      commercial release specifications are eligible for inclusion.Each case will be individually
      assessed for the expected benefit risk profile prior to release to the patient. Following the
      infusion of OOS tisagenlecleucel, the patient will be followed for 3 months on this study.
    
  